drugset

drugset / Trial / NCT00407056

Study of Difluprednate Ophthalmic Emulsion in the Treatment of Severe Uveitis

NCT00407056 ↗

Phase 3 Completed 20 enrolled Sirion Therapeutics, Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this phase 3 open-labeled study is to determine if difluprednate ophthalmic emulsion is effective in the treatment of severe uveitis.

Timeline

Start: 2002-08
Primary completion: —
Completion: 2003-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Difluprednate	Small molecule	0.05 %	—

Indications